摘要
吉西他滨是近年来治疗晚期非小细胞肺癌的有效新药。国外大量临床试验已经证实其单一用药有效率稳定在 2 0 %以上 ,中位生存 34周 ,可明显改善肿瘤相关症状 ,毒性易耐受。
Gemcitabine is a new active drug in the treatment of advanced non small cell lung cancer (NSCLC). It is validated that the response rate of the single agent gemcitabine was consistently above 20%, median survival was 34 weeks and it could improve the disease related symptoms with well toleranced toxicities by many clinical studies. This report reviews the clinical studies of gemcitabine in the patients with advanced NSCLC.
出处
《中国癌症杂志》
CAS
CSCD
2001年第1期74-77,80,共5页
China Oncology
